Accelerate Diagnostics (AXDX) Stock Price, News & Analysis

Company Overview

Accelerate Diagnostics, Inc. is a clinical-stage in vitro diagnostics company specializing in the rapid identification and antimicrobial susceptibility testing of infectious diseases. The company’s core offering is the Accelerate Pheno system, a fully automated platform designed to deliver both organism identification and phenotypic antimicrobial susceptibility results directly from positive blood cultures. By leveraging proprietary Morphokinetic Cellular Analysis (MCA) technology, Accelerate Diagnostics aims to significantly reduce the time required to guide appropriate antimicrobial therapy for patients with bloodstream infections.

Central to the company’s product portfolio is the PhenoTest BC Kit, which integrates with the Accelerate Pheno system to deliver actionable results in as little as seven hours, compared to traditional methods that can take up to 48 hours or more. In addition to its blood culture solutions, Accelerate Diagnostics is advancing its pipeline to include respiratory pathogen panels and other infectious disease targets, positioning the company to address a broad spectrum of hospital and reference laboratory needs.

Founded in 2008 and headquartered in Tucson, Arizona, Accelerate Diagnostics completed its initial public offering on the NASDAQ in 2019 under the ticker AXDX. Since inception, the company has secured regulatory clearances in the United States, European Union and other key markets, and has formed strategic collaborations with global distribution partners to expand its installed base. Accelerate Diagnostics has also invested in clinical research partnerships to validate the clinical impact and health economic benefits of its rapid diagnostic workflow.

Accelerate Diagnostics serves hospitals, academic medical centers and reference laboratories in North America, Europe and select Asia-Pacific markets. The company is guided by an experienced management team with deep expertise in medical diagnostics, regulatory affairs and commercial operations, alongside a board of directors that includes leaders in infectious disease research, laboratory medicine and healthcare innovation.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.03 to $1.18
• 52-Week Range: N/A
• Volume: 53.64 million shs
• Average Volume: 542,464 shs
• Market Capitalization: $857 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Buy

Accelerate Diagnostics Stock Analysis - MarketRank™

Accelerate Diagnostics scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Accelerate Diagnostics.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Accelerate Diagnostics are expected to grow in the coming year, from ($2.30) to ($2.00) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Accelerate Diagnostics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Accelerate Diagnostics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for AXDX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Accelerate Diagnostics does not currently pay a dividend.

Dividend Growth

Accelerate Diagnostics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -1.62

Short Interest

There is no current short interest data available for AXDX.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: N/A

News Sentiment

Accelerate Diagnostics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Accelerate Diagnostics insiders have not sold or bought any company stock.

Percentage Held by Insiders

43.60% of the stock of Accelerate Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 17.14% of the stock of Accelerate Diagnostics is held by institutions.

AXDX Stock Analysis - Frequently Asked Questions

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) released its earnings results on Thursday, March, 20th. The medical research company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.50) by $0.13. The medical research company earned $2.82 million during the quarter, compared to analysts' expectations of $3 million.

When did Accelerate Diagnostics' stock split?

Accelerate Diagnostics shares reverse split before market open on Wednesday, July 12th 2023.The 1-10 reverse split was announced on Wednesday, July 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Accelerate Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Accelerate Diagnostics investors own include Himax Technologies (HIMX), Sangamo Therapeutics (SGMO), Magnachip Semiconductor (MX), Universal Display (OLED), Energy Transfer (ET), Fluidigm (FLDM) and Netflix (NFLX).

Company Calendar

• Last Earnings: 3/20/2025
• Today: 7/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:AXDX
• CIK: 727207
• Web: acceleratediagnostics.com
• Phone: (520) 365-3100
• Fax: 520-269-6580
• Employees: 220
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$61.62 million
• Net Margins: -471.83%
• Pretax Margin: -444.14%
• Return on Equity: N/A
• Return on Assets: -191.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.50
• Quick Ratio: 1.34

Sales & Book Value

• Annual Sales: $11.70 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.37) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 25,210,000
• Free Float: 14,125,000
• Market Cap: $857 thousand
• Optionable: Optionable
• Beta: 0.22